Ratings PDS Limited Bombay S.E.

Equities

PDSL

INE111Q01021

Market Closed - Bombay S.E. Other stock markets 11:00:50 13/05/2024 BST			5-day change	1st Jan Change
439.6 ^INR	-0.07%		+1.48%	-20.62%

05-10	NetScientific says PDS Biotech's Versamune meets endpoints	AN
05-10	PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company sustains low margins.
With a 2024 P/E ratio at 26.79 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Apparel & Accessories

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
PDS LIMITED	-20.62%	695M		C
CHRISTIAN DIOR SE	+4.38%	144B	-	A-
LULULEMON ATHLETICA INC.	-30.97%	44.44B		C
MONCLER S.P.A.	+12.57%	18.47B		A
RALPH LAUREN CORPORATION	+15.92%	10.69B		B
LEVI STRAUSS & CO.	+36.76%	9B		C
LI NING COMPANY LIMITED	+2.87%	7.23B		C-
PVH CORP.	-6.64%	6.45B		A-
BOSIDENG INTERNATIONAL HOLDINGS LIMITED	+30.48%	6.39B		B
GILDAN ACTIVEWEAR INC.	+4.82%	5.67B		A

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes